相关实验视频
Updated: Jul 22, 2025

07:16
Biochemical Titration of Glycogen In vitro
Published on: November 24, 2013
28.5K
法国关于管理三型糖原储存疾病的建议
Camille Wicker1, Aline Cano2, Valérie Decostre3
1Maladies métaboliques et hépatiques pédiatriques, CHRU Hautepierre, 1 Avenue Molière, 67200, Strasbourg, France.
European journal of medical research
|July 24, 2023
概括
这项法国国家诊断和医疗保健协议 (PNDS) 指导卫生专业人员管理三型糖原储存疾病 (GSD III). 它详细介绍了GSD III患者的最佳诊断,监测和治疗途径.
科学领域:
- 医学遗传学 医学遗传学
- 儿科内分泌学 儿科内分泌学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 糖原储存疾病III型 (GSD III) 是一种罕见的遗传代谢障碍.
- 最佳的管理需要一个协调的,多学科的方法.
- 现有的指导方针可能无法完全解决GSD III护理的复杂性.
研究的目的:
- 提交法国国家诊断和医疗保健协议 (PNDS) 针对GSD III.
- 为医疗保健专业人员提供一个标准化的患者护理框架.
- 提高GSD III的诊断准确性,治疗策略和监测协议.
主要方法:
- 根据专家的共识制定国家协议.
- 包括诊断标准,推的调查和监测时间表.
- 关于治疗干预和医疗保健组织的指导.
主要成果:
- 已经为GSD III建立了一个全面的PNDS.
- 该协议概述了用于诊断和严重程度评估的具体测试.
- 它详细介绍了治疗方法和患者监测的组织方面.
结论:
- PNDS是医疗保健提供者管理 GSD III. 的实用工具.
- 它旨在规范护理并改善GSD III患者的治疗结果.
- 医生的责任在个人患者护理中仍然至关重要.
相关概念视频
Hypoglycemia and Glucagon
302
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
302
Diabetes: Management and Pharmacotherapy
317
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
317
Cystic Fibrosis: Management
194
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
194
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Nephrotic Syndrome III : Nursing Management
19
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
19
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K

